Correlation Between Dermata Therapeutics and Corbus Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Dermata Therapeutics and Corbus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Dermata Therapeutics and Corbus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Dermata Therapeutics and Corbus Pharmaceuticals Holding, you can compare the effects of market volatilities on Dermata Therapeutics and Corbus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Dermata Therapeutics with a short position of Corbus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Dermata Therapeutics and Corbus Pharmaceuticals.

Diversification Opportunities for Dermata Therapeutics and Corbus Pharmaceuticals

0.64
  Correlation Coefficient

Poor diversification

The 3 months correlation between Dermata and Corbus is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Dermata Therapeutics and Corbus Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Corbus Pharmaceuticals and Dermata Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Dermata Therapeutics are associated (or correlated) with Corbus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Corbus Pharmaceuticals has no effect on the direction of Dermata Therapeutics i.e., Dermata Therapeutics and Corbus Pharmaceuticals go up and down completely randomly.

Pair Corralation between Dermata Therapeutics and Corbus Pharmaceuticals

Given the investment horizon of 90 days Dermata Therapeutics is expected to generate 0.95 times more return on investment than Corbus Pharmaceuticals. However, Dermata Therapeutics is 1.05 times less risky than Corbus Pharmaceuticals. It trades about -0.03 of its potential returns per unit of risk. Corbus Pharmaceuticals Holding is currently generating about -0.13 per unit of risk. If you would invest  160.00  in Dermata Therapeutics on September 3, 2024 and sell it today you would lose (47.00) from holding Dermata Therapeutics or give up 29.38% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Dermata Therapeutics  vs.  Corbus Pharmaceuticals Holding

 Performance 
       Timeline  
Dermata Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Dermata Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Corbus Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Corbus Pharmaceuticals Holding has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's fundamental drivers remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Dermata Therapeutics and Corbus Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Dermata Therapeutics and Corbus Pharmaceuticals

The main advantage of trading using opposite Dermata Therapeutics and Corbus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Dermata Therapeutics position performs unexpectedly, Corbus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will offset losses from the drop in Corbus Pharmaceuticals' long position.
The idea behind Dermata Therapeutics and Corbus Pharmaceuticals Holding pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Complementary Tools

Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Bonds Directory
Find actively traded corporate debentures issued by US companies
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges